Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.

Bisht S, Schlesinger M, Rupp A, Schubert R, Nolting J, Wenzel J, Holdenrieder S, Brossart P, Bendas G, Feldmann G.

J Nanobiotechnology. 2016 Jul 11;14(1):57. doi: 10.1186/s12951-016-0209-6.

2.

Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.

Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T, Kunzmann V, Stoetzer OJ, Suttmann I, Braess J, Birkmann J, Roessler M, Moritz B, Kraff S, Salamone SJ, Jaehde U.

Clin Colorectal Cancer. 2016 May 7. pii: S1533-0028(16)30049-4. doi: 10.1016/j.clcc.2016.04.001. [Epub ahead of print]

PMID:
27256667
3.

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.

Stingl JC, Kaumanns KL, Claus K, Lehmann ML, Kastenmüller K, Bleckwenn M, Hartmann G, Steffens M, Wirtz D, Leuchs AK, Benda N, Meier F, Schöffski O, Holdenrieder S, Coch C, Weckbecker K.

BMC Fam Pract. 2016 Apr 26;17:49. doi: 10.1186/s12875-016-0447-6.

4.

Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.

Pilzweger C, Holdenrieder S.

Diagnostics (Basel). 2015 Jun 16;5(2):219-53. doi: 10.3390/diagnostics5020219. Review.

5.

In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors".

Dayyani F, Morgenstern D, Holdenrieder S.

J Oncol Pract. 2016 Mar;12(3):273-4. doi: 10.1200/JOP.2015.009241. Epub 2016 Feb 2. No abstract available.

6.

Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.

Yörüker EE, Holdenrieder S, Gezer U.

Clin Chim Acta. 2016 Apr 1;455:26-32. doi: 10.1016/j.cca.2016.01.016. Epub 2016 Jan 18. Review.

PMID:
26797671
7.

Histone Methylation Marks on Circulating Nucleosomes as Novel Blood-Based Biomarker in Colorectal Cancer.

Gezer U, Yörüker EE, Keskin M, Kulle CB, Dharuman Y, Holdenrieder S.

Int J Mol Sci. 2015 Dec 11;16(12):29654-62. doi: 10.3390/ijms161226180.

8.

Apoptosis-related biomarkers in patients with gastrointestinal cancer.

Dressen K, Hermann N, Manekeller S, Walgenbach-Bruenagel G, Schildberg FA, Hettwer K, Uhlig S, Kalff JC, Holdenrieder S.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1062-4. doi: 10.5414/CPCES14EA11. No abstract available.

9.

Apoptosis-related biomarkers in patients with gynecological cancer.

Hermann N, Dressen K, Schroeder L, Debald M, Keyver-Paik M, Abramian A, Walgenbach-Bruenagel G, Schildberg FA, Hettwer K, Uhlig S, Kuhn W, Holdenrieder S.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1059-61. doi: 10.5414/CPCES14EA10. No abstract available.

PMID:
26521925
10.

Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.

Coenen M, Hinze AV, Mengel M, Fuhrmann C, Lüdenbach B, Zimmermann J, Dykstra V, Fimmers R, Viviani R, Stingl J, Holdenrieder S, Müller M, Hartmann G, Coch C.

BMC Pharmacol Toxicol. 2015 Sep 22;16:25. doi: 10.1186/s40360-015-0025-x.

11.

Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement.

Sinning JM, Wollert KC, Sedaghat A, Widera C, Radermacher MC, Descoups C, Hammerstingl C, Weber M, Stundl A, Ghanem A, Widder J, Vasa-Nicotera M, Mellert F, Schiller W, Bauersachs J, Zur B, Holdenrieder S, Welz A, Grube E, Pencina MJ, Nickenig G, Werner N, Kempf T.

Am Heart J. 2015 Oct;170(4):821-9. doi: 10.1016/j.ahj.2015.07.003. Epub 2015 Jul 10.

PMID:
26386807
12.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

13.

Assessment of circulating serum DNA integrity in colorectal cancer patients.

Yörüker EE, Özgür E, Keskin M, Dalay N, Holdenrieder S, Gezer U.

Anticancer Res. 2015 Apr;35(4):2435-40.

PMID:
25862911
14.

Androgen Stimulation of PCA3 and miR-141 and Their Release from Prostate Cancer Cells.

Gezer U, Tiryakioglu D, Bilgin E, Dalay N, Holdenrieder S.

Cell J. 2015 Winter;16(4):488-93. Epub 2015 Jan 13.

15.

Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer.

Kriebel S, Schmidt D, Holdenrieder S, Goltz D, Kristiansen G, Moritz R, Fisang C, Müller SC, Ellinger J.

PLoS One. 2015 Jan 28;10(1):e0117284. doi: 10.1371/journal.pone.0117284. eCollection 2015.

16.

Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay.

Hermann N, Dreßen K, Schildberg FA, Jakobs C, Holdenrieder S.

World J Methodol. 2014 Dec 26;4(4):219-31. doi: 10.5662/wjm.v4.i4.219. eCollection 2014 Dec 26.

17.

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.

Haas M, Kern C, Kruger S, Michl M, Modest DP, Giessen C, Schulz C, von Einem JC, Ormanns S, Laubender RP, Holdenrieder S, Heinemann V, Boeck S.

Tumour Biol. 2015 Apr;36(4):2631-40. doi: 10.1007/s13277-014-2885-x. Epub 2014 Dec 4.

PMID:
25472579
18.

Characterizing the genetic basis of innate immune response in TLR4-activated human monocytes.

Kim S, Becker J, Bechheim M, Kaiser V, Noursadeghi M, Fricker N, Beier E, Klaschik S, Boor P, Hess T, Hofmann A, Holdenrieder S, Wendland JR, Fröhlich H, Hartmann G, Nöthen MM, Müller-Myhsok B, Pütz B, Hornung V, Schumacher J.

Nat Commun. 2014 Oct 20;5:5236. doi: 10.1038/ncomms6236.

PMID:
25327457
19.

[Detection of cell-free lncRNA in serum of cancer patients].

Kohls K, Schmidt D, Holdenrieder S, Müller SC, Ellinger J.

Urologe A. 2015 Jun;54(6):819-25. doi: 10.1007/s00120-014-3655-5. German.

PMID:
25312755
20.

Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.

Korse CM, Holdenrieder S, Zhi XY, Zhang X, Qiu L, Geistanger A, Lisy MR, Wehnl B, van den Broek D, Escudero JM, Standop J, Hu M, Molina R.

Clin Chim Acta. 2015 Jan 1;438:388-95. doi: 10.1016/j.cca.2014.09.015. Epub 2014 Sep 28.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk